Literature DB >> 8666523

Immunization against hepatitis B through adoptive transfer of immunity.

D Shouval1, Y Ilan.   

Abstract

Clearance of hepatitis B virus (HBV) infection requires an effective T-cell-dependent humoral response that is often defective in HBV carriers and in immunosuppressed patients. We have shown in mice and humans that bone marrow (BM)-derived memory cells, capable of producing antibodies to the HBV envelope and nucleocapsid antigens, are transferable from BM donors (BMD) to their recipients. BMD BALB/c mice were immunized with recombinant HBV surface antigen (HBsAg), and BM from anti-HBs-positive donors was transplanted to irradiated recipient mice, who seroconverted to anti-HBs within 30 days of bone marrow transplantation (BMT), and responded to booster vaccination. In a similar manner, 19/26 human BM recipients, who received their HLA-matched BM from BMDs immunized once with HBsAg, seroconverted within several weeks after BMT. Antibodies to HBsAg were also observed in 3 recipients of peripheral blood lymphocytes (PBL) obtained from HLA-matched immunized human donors. Finally, clearance of HBsAg and HBV DNA was observed in an HBsAg carrier with leukemia who received BMT from his HLA-matched anti-HBc+/anti-HBs+ brother. These results indicate that adoptive transfer of immunity to HBV may be achieved through immunization of BM or PBL donors against HBV.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8666523     DOI: 10.1159/000150413

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  3 in total

1.  Distinct genotypic distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease.

Authors:  P C Woo; C Y Lo; S K Lo; H Siau; J S Peiris; S S Wong; W K Luk; T M Chan; W W Lim; K Y Yuen
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

2.  Immune therapy for hepatocellular carcinoma.

Authors:  Yaron Ilan
Journal:  Hepatol Int       Date:  2013-12-20       Impact factor: 6.047

3.  Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease.

Authors:  Joanne Filicko-O'Hara; Dolores Grosso; Phyllis R Flomenberg; Thea M Friedman; Janet Brunner; William Drobyski; Andres Ferber; Irina Kakhniashvili; Carolyn Keever-Taylor; Bijoyesh Mookerjee; Julie-An Talano; John I Wagner; Robert Korngold; Neal Flomenberg
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-08       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.